- 1 Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and
- 2 responses to vaccination
- 3 Lavanya Visvabharathy<sup>1\*¶</sup>, Barbara Hanson<sup>1,3</sup>, Zachary Orban<sup>1</sup>, Patrick H. Lim<sup>1</sup>, Nicole Palacio<sup>2</sup>,
- 4 Rishi Jain<sup>1</sup>, Eric Michael Liotta<sup>1</sup>, Pablo Penaloza-MacMaster<sup>2</sup>, Igor J. Koralnik<sup>1\*</sup>
- <sup>1</sup>Ken and Ruth Davee Department of Neurology, Feinberg School of Medicine, Northwestern
- 6 University, Chicago IL 60611 USA
- <sup>2</sup>Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern
- 8 University, Chicago IL 60611 USA

- 9 <sup>3</sup>Rush Medical College, Chicago IL 60612 USA
- \*Corresponding authors: Igor J. Koralnik, M.D.: <u>igor.koralnik@northwestern.edu</u>;
- Lavanya Visvabharathy, Ph.D: lavanya.visvabharathy@northwestern.edu
- 13 ¶ Lead contact: Lavanya Visvabharathy, Ph.D

Summary

The high prevalence of post-acute sequelae of SARS-CoV-2 infection (PASC) is a significant health concern. In particular, virus-specific immunity in patients who suffer from chronic neurologic symptoms after mild acute COVID remain poorly understood. Here, we report that neuro-PASC patients have a specific signature composed of humoral and cellular immune responses that are biased towards different structural proteins compared to healthy COVID convalescents. Interestingly, the severity of cognitive deficits or quality of life markers in neuro-PASC patients are associated with reduced effector molecule expression in memory T cells. Furthermore, we demonstrate that T cell responses to SARS-CoV-2 mRNA vaccines are aberrantly elevated in longitudinally sampled neuro-PASC patients compared with healthy COVID convalescents. These data provide a framework for the rational design of diagnostics and predictive biomarkers for long-COVID disease, as well as a blueprint for improved therapeutics.

Keywords: COVID-19 immunity, T cell memory, neuro-PASC, long-COVID, vaccine-induced immunity

### Introduction

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

SARS-CoV-2 is the causative agent of a worldwide pandemic that started in Wuhan, China in December, 2019. There have been more than 200 million cases and over 4 million deaths globally attributable to COVID-19 disease (Center, 2021). Although highly effective vaccines are now used to prevent severe disease and death caused by SARS-CoV-2, long-term sequelae of SARS-CoV-2 infection are increasingly becoming an important medical concern. SARS-CoV-2 infection is associated with presentations ranging from asymptomatic carriage to severe multi-organ dysfunction (Li et al., 2020; Liguori et al., 2020; Syed et al., 2020). Globally, the estimated fatality rate following SARS-CoV-2 infection is approximately 1-2%, but not all patients recover to their baseline states (Higgins et al., 2020). "Long COVID" affects an estimated 10-40% of all infected people and includes symptoms persisting more than 28 days after diagnosis of SARS-CoV-2 infection, termed "post-acute sequelae of SARS-CoV-2 infection" or PASC (Ladds et al., 2020; Vehar et al., 2021). Greater than two-thirds of hospitalized COVID-19 patients experience ongoing fatigue, breathlessness, and psychiatric issues such as post-traumatic stress disorder (PTSD) 4-8 weeks after discharge (Halpin et al., 2021). However, the vast majority of people with COVID experience mild disease not requiring hospitalization, and more than half of these have symptoms persisting more than 4 months after acute infection (Petersen et al., 2020). Many people who survived Middle-East respiratory virus (MERS) and the original SARS-CoV pandemic also experienced PTSD and neurological impairments up to 3.5 years after acute infection (Ahmed et al., 2020; Lam et al., 2009). More recent studies on recovered COVID-19 patients showed significant cognitive deficits in attention, working memory, and emotional processing months after acute infection had resolved (Hampshire, 2021). Here, we focus on a cohort of mostly non-hospitalized long-COVID patients

presenting with neurological symptoms ("neuro-PASC") who exhibit a reduction in quality of life with regards to cognitive and fatigue parameters (Graham et al., 2021).

Numerous studies suggest that a robust T cell response is necessary for viral clearance in infected individuals. In particular, CD4<sup>+</sup> T cell responses directed against the Spike protein were found in 100% of healthy COVID convalescents, while 70% displayed Spike-specific CD8<sup>+</sup> T cell responses (Grifoni et al., 2020). Another study found that memory T cells cross-reactive to SARS-CoV-2 nucleocapsid (N) protein persisted in people exposed to SARS-CoV up to 17 years after the epidemic of 2003 (Le Bert et al., 2020). Post-mortem autopsies of COVID-19 patients have shown that innate immune cells but not lymphocytes are enriched in lung infiltrate, and that these patients exhibit impaired germinal center formation in lung draining lymph nodes (Duan et al., 2020). Additional studies have shown that CD8<sup>+</sup> T cell depletion after SARS-CoV-2 infection of rhesus macaques impairs anamnestic responses, suggesting a role for T cell memory in long-term immunity to SARS-CoV-2 infection (McMahan et al., 2021).

Most studies on T cell responses to SARS-CoV-2 have focused on acutely symptomatic individuals. However, adaptive immune responses in patients who remain chronically symptomatic remain largely unexplored. Our studies indicate that neuro-PASC patients ("CN") had hypo-functional Ag-specific CD8+ T cell memory responses SARS-CoV-2 compared with healthy convalescents ("CC") and enhanced reactivity to N and M proteins compared with CC subjects. The severity of cognitive deficits and quality of life markers were associated with enhanced polarization in cytolytic granule expression in memory T cell subsets. Finally, we demonstrate that T cell responses to SARS-CoV-2 vaccination are more robust and display aberrant kinetics in neuro-PASC patients compared with control groups. Together, these data demonstrate a wide-scale dysfunction in SARS-CoV-2 T cell memory in neuro-PASC long-

- hauler patients, with important implications for both appropriate diagnostic and vaccination
- 75 strategies.

### **Results**

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

Clinical characteristics of neuro-PASC patients

We enrolled a total of 111 participants prior to SARS-CoV-2 vaccination drawn from the neuro-COVID-19 outpatient clinic at Northwestern Memorial Hospital or from the surrounding Chicago area. This included 56 neuro-PASC "CN" patients (confirmed RT-PCR+ or anti-SARS-CoV-2 Spike IgG+) meeting Infectious Disease Society of America clinical criteria for COVID-19 starting after February 2020 and had neurologic symptoms lasting at least 6 weeks postinfection, as previously reported (Graham et al., 2021). Among those, 48 (86%) were never hospitalized for pneumonia or hypoxemia. We additionally recruited 24 healthy COVID convalescents without lasting symptoms (RT-PCR+ or seropositive for anti- SARS-CoV-2 Spike RBD IgG, "CC"); and 31 healthy controls who were RT-PCR- and seronegative for SARS-CoV-2 Spike-IgG ("HC"; study description in Fig. 1A). CN patients displayed a constellation of neurological symptoms similar to those previously reported by our group and in other studies (Fig. 1B). In addition, we utilized standardized methods to quantify their quality of life and cognitive disturbances relative to healthy convalescents. Results from the patient reported outcomes information system (PROMIS-57) survey (Tang et al., 2019) showed that CN patients scored significantly lower on physical function and higher on anxiety, depression, pain and other metrics compared with CC subjects or the national average (Fig. 1C). NIH toolbox tests administered to CN patients to assess their cognitive function (Weintraub et al., 2013) showed CN patients had significantly lower T scores in the attention module, which was indicative of cognitive dysfunction relative to the national average (Fig. 1D).

*Neuro-PASC* is associated with a distinct immunodominance hierarchy.

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

To determine whether neuro-PASC included alterations in the magnitude and/or specificity of Ag-specific T cell responses in CN patients, we performed ELISPOT for SARS-CoV-2-specific T cells. PBMC from each subject were cultured in the presence of peptide pools derived from spike (S), nucleocapsid (N), or membrane (M) proteins of SARS-CoV-2 (Fig. S1). The magnitude and specificity of both IFN-y and IL-2 responses to S sub-pools were similar between CN and CC subjects (Fig. 2A-B). However, CN subjects produced high levels of IFN-y against all sub-pools of N and M proteins, while CC subjects had a specificity for the N1 pool and lower responses against all M pools (Fig. 2C-D), indicative of different immunodominance hierarchies between groups. No significant differences were found in IL-2 production, and healthy controls exhibited some response to N pools likely caused by cross-reactivity with endemic coronaviruses (Fig. 2E-F). Antibody titers against the Spike receptor-binding domain (RBD) did not differ between CN and CC groups (Fig. 2G). Interestingly, high IgG titers did not correlate with the magnitude of the IFN-y T cell response against S2 or S3 peptide pools comprising the 2 halves of the Spike RBD (Fig. S2). CD4<sup>+</sup> Tfh cells display opposing reactivity to SARS-CoV-2 N- and M-proteins in neuro-PASC vs. healthy COVID convalescents RNA-Seq analysis of CD4<sup>+</sup> T cells from hospitalized and non-hospitalized COVID-19 patients showed that severe disease is associated with elevated CD4<sup>+</sup> T follicular helper (Tfh) proportions relative to patients with mild disease (Meckiff et al., 2020). We sought to determine whether Tfh responses (gating in Fig. S3) that prime antibody production from plasma B cells could similarly differentiate neuro-PASC CN patients from CC individuals. Immunophenotyping showed that there were no differences in total percentages of T cell subsets, including Tfh cells,

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

between groups (Fig. S4). The activation-induced marker (AIM) assay has been previously used to detect TCR-mediated activation of T cells (Grifoni et al., 2020) and we used this method to investigate Tfh cell activation (gating for Tfh cells in Fig. S3). N protein-specific CD134<sup>+</sup>CD137<sup>+</sup> (AIM<sup>+</sup>) CD4 Tfh cells were significantly elevated in CN compared with CC subjects, while the opposite trend was observed in M protein-specific activation (Fig. 3A-B). No differences were seen in Tfh activation between CN and CC groups across Spike peptide pools (Fig. 3B). The magnitude of N- and M-specific Tfh cell activation did not correlate with the time since acute infection in either CN or CC patients (Fig. 3C-D) despite reports showing that antibody titers against N protein decrease rapidly post-infection (Van Elslande et al., 2021) which would presumably lead to decreased N-specific Tfh cell activation over time. N-specific IgG titers were significantly elevated in CN compared with CC subjects (Fig. 3E), consistent with the enhanced N-specific CD4<sup>+</sup> Tfh cell activation shown in 3B. Similar to Tfh cells, there was no correlation between anti-N IgG titers and time post-symptom onset for either CN or CC subjects (Fig. S5A). Studies have shown that IgG titers against N protein decline to undetectable levels in 40% of COVID convalescents within 4 months (Muecksch et al., 2021). We largely did not observe this decline in CN patients despite collecting their blood samples an average of 193 days post-symptom onset (Fig. 1B). CD4<sup>+</sup> T cell polyfunctionality to Spike protein differs in neuro-PASC vs. healthy COVID convalescents Cytotoxic CD4<sup>+</sup> T cells acquire the ability to produce cytolytic granules upon activation with cognate viral antigen (Goubard et al., 2015; Sledzinska et al., 2020). Viral infections specifically induce expansion of the memory CD4<sup>+</sup> T effector memory cells re-expressing CD45RA (TEMRA) population that secrete copious amounts of cytolytic granules upon antigen

encounter (Tian et al., 2017). We therefore investigated whether Ag-specific production of multiple granzymes and cytokines in CD4<sup>+</sup> T cells were altered between groups. While CN and HC groups maintained polyfunctionality and polarization, CC subjects had significantly more polyfunctional CD4<sup>+</sup> T cells producing granzymes A, B, and M after Spike pool stimulation (category 2 in yellow, Fig. 3F). A heatmap quantifying this effect showed that CC had a 2-fold elevation in category 2 effector molecules over CN subjects (Fig. 3G). This data suggests that cytotoxic responses to Spike protein in CD4<sup>+</sup> T cells from healthy COVID-19 convalescents significantly differ from those experiencing chronic neurologic symptoms.

# *CD8*<sup>+</sup> *memory T cell functionality in neuro-PASC patients*

CD8<sup>+</sup> memory T cells are crucial for protection from recurrent viral infections (Mockus et al., 2019). Studies have shown that memory CD8<sup>+</sup> cells can persist for several years after patient exposure to SARS-CoV (Chen et al., 2005) and that acute mild disease induces stronger Ag-specific CD8<sup>+</sup> memory responses than severe disease (Peng et al., 2020). However, little is known about whether CD8<sup>+</sup> memory differs in neuro-PASC long-haulers vs. healthy COVID convalescents months after acute infection resolves. To address this, we probed the dynamics of CD8<sup>+</sup> TEM, TCM, and TEMRA activation in CN, CC, and HC subjects. CD8<sup>+</sup> TEM were significantly activated by various S, N, and M peptide pools in CC subjects while remaining relatively quiescent after antigen stimulation in CN patients (Fig. 4A-B). CD8<sup>+</sup> TEMRA are terminally differentiated memory cells with distinct transcriptional programs that respond quickly to viral infections (Tian et al., 2019). Total percentages of CD8<sup>+</sup> TEMRA cells were significantly elevated in CN compared with CC and HC groups (Fig. 4C), but despite their increased numbers, CD8<sup>+</sup> TEMRA cells were less activated by the S3/4 peptide pool in CN

patients and showed a trend towards decreased activation after N pool stimulation compared with CC subjects (Fig. 4D-E).

Similarly, antigen stimulation resulted in altered cytokine polarization in CD8<sup>+</sup> T cell subsets in CN and CC groups. Effector molecule production in CD8<sup>+</sup> T cells was similar across groups in the unstimulated condition, despite showing some statistically significant differences in perforin production (Fig. S6B). However, stimulation with the S3/4 pool induced greater TNF-α production in the CC group while CN patients had enhanced IL-6 production to the same stimulus (Fig. 4F). S pool stimulation also induced CD8<sup>+</sup> TEMRA cells from the CC group to produce elevated levels of granzymes, which was not seen in CN or HC groups (Fig. 4G, black lines), demonstrating that CD8<sup>+</sup> T cell subsets display decreased functionality in CN vs. CC patients after stimulation.

Impaired cognition and decreased quality of life metrics correlate with distinct patterns of polyfunctionality in memory T cell subsets

Having shown that Tfh and T cell memory responses differed between patient groups, we next sought to probe whether within-group differences in T cell responses correlated with various clinical measures in CN patients. We found a significant positive correlation between the magnitude of IFN-γ production to N protein and higher pain interference scores (Fig. 5A). There was also a trend towards a positive correlation between high scores for depression and the magnitude of the N-specific T cell response (Fig. 5B). To look at associations between clinical parameters and T cell activation, we separated T scores from NIH Toolbox or PROMIS-57 measurements (Fig. 1C-D) into quartiles and only the lowest and highest groups (Q1 vs. Q4) were used for analysis (Fig. S7A, red boxes). CN subjects reporting high (Q4) pain interference scores produced significantly less granzyme A or B and more IL-6 than those with low scores

(Fig. 5C-D) from CD8<sup>+</sup> T cells after S pool stimulation. Further, patients reporting low

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

depression scores had highly polyfunctional Spike-specific CD8<sup>+</sup> TEM, while those reporting high levels of depression had TEM producing ~3-fold higher granzymes A, B, and M alone (category 2; Fig. 5E, F). The severity of cognitive impairment could also be significantly correlated with T cell responses. Q1 patients scoring low on executive function tests had CD8<sup>+</sup> TCM polarized towards granzymes A, B, M and perforin production (category 1), while those in Q4 were biased to produce granzymes A, B, and perforin (Fig. 5G-H). Similar analyses were performed for other CD8<sup>+</sup> and CD4<sup>+</sup> memory T cell subsets, and significant differences by quartile were also found in correlations with depression, processing speed, working memory, and global pain (Fig. S7B-K). These data show that the severity of cognitive deficits or quality of life measures can be significantly correlated with differences in SARS-CoV-2-specific memory T cell function. SARS-CoV-2 vaccination induces sustained elevation in Spike-specific IFN-y responses in neuro-PASC but not healthy COVID convalescents SARS-CoV-2 mRNA vaccines have been proven to be highly effective against contracting infection in the short-term in both clinical trials and in real-world settings (Haas et al., 2021; Polack et al., 2020). However, neither clinical trials nor field studies specifically characterized the vaccine-induced immune response in long-COVID patients, and it is similarly unknown whether vaccination can ameliorate long-haul symptoms. One prospective study showed that vaccination did not significantly worsen symptoms in 22 patients with long-COVID (Arnold et al., 2021), but also did not provide evidence to show any decrease in symptoms. To address how vaccine-induced immunity evolves over time in neuro-PASC long-haulers, we conducted a longitudinal vaccine study assessing Spike-specific antibody and T cell responses

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

over the course of 6 months post-vaccination (study design and patient demographics in Fig. 6A-B). While this study is ongoing, we report data from the first 4 months comparing responses in CN, CC, and HC subjects (n for each group per study visit shown in Fig. S8). Vaccination with either Pfizer or Moderna mRNA vaccines induced robust SARS-CoV-2 Spike RBD IgG titers in all groups tested by 3 weeks post-2<sup>nd</sup> dose, with the highest titers found in CN patients. Antibody titers were at similar levels in all groups by 3 months post-1<sup>st</sup> dose, but trended higher in CN than in HC subjects at visit (V)4 (Fig. 6C). In parallel, we measured Spike-specific T cell responses in study subjects. The magnitude and kinetics of the T cell response in CC and HC subjects were similar and peaked at V3. However, CN patients had significantly elevated Spike-specific T cell responses compared with either HC or CC groups at V2 after the vaccination boost (Fig. 6D; individual pool data shown in Fig. S9). IFN-γ-specific T cell responses remained high at 4 months post-vaccination in CN patients while not significantly differing from pre-vaccination levels in both CC and HC subjects. To our knowledge, these are the first data that longitudinally compare the T cell response to vaccination in neuro-PASC patients with healthy COVID convalescents and unexposed individuals. Overall, our study demonstrates that neuro-PASC patients have elevated IFN-y responses to N and M proteins, enhanced Ag-specific activation of Tfh cells, sustained anti-N IgG production, and deficient activation of multiple CD8<sup>+</sup> memory T cell subsets compared with healthy COVID-19 convalescents. There were also correlations between the severity of cognitive deficits or quality of life impairments and Ag-specific cytokine signatures (Fig. 5, S7). Importantly, vaccination resulted in sustained enhancements in the magnitude of Spike-specific T cell responses in neuro-PASC patients vs. all other groups, regardless of prior COVID exposure. Together, we show that CN patients exhibit a large-scale dysfunction in multiple

- aspects of the memory T cell response which may inform treatment and/or vaccination options
- down the line.

COVID-19 is well-recognized as a multi-organ disease with long-term sequelae

### Discussion

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

associated with neurological disease. PASC has been reported in up to 87% of those hospitalized with SARS-CoV-2 pneumonia and in up to 40% of those with mild disease who do not require hospitalization (Havervall et al., 2021; Hirschtick et al., 2021; Mahase, 2020). SARS-CoV-2 vaccines have decreased the rates of SARS-CoV-2 infection and mortality in unexposed individuals, but it is not clear that vaccines help to ameliorate long-COVID symptoms in previously infected individuals (Arnold et al., 2021) and thus further study is needed to inform treatment options. Long-term sequelae after other coronavirus infections can persist for years (Ahmed et al., 2020); therefore, it is important to specifically characterize SARS-CoV-2-specific immune responses in long-COVID patients. Most studies on effector and memory T cell responses to SARS-CoV-2 have focused on acute infection or healthy convalescents as opposed to those with long-COVID (Rodda et al., 2021; Sekine et al., 2020; Weiskopf et al., 2020). We aimed to fill this knowledge gap and determine whether and how T cell phenotype and function differ in patients with neuro-PASC and healthy COVID-19 convalescents. Clinically, neuro-PASC resembles myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), which many patients report as a post-viral infectious complication (Rasa et al., 2018). The causes of ME/CFS remain elusive, and the underlying mechanisms of neuro-PASC remain similarly unknown. It is possible that direct infection of the brain is responsible for neuro-PASC symptoms. It is believed that SARS-CoV-2 gains entry into the central nervous system through the olfactory bulb and has been shown to infect neurons in vitro, which is supported by findings of viral protein expression in cortical neurons from post-mortem autopsies (Klingenstein et al., 2020; Song et al., 2021). However, another study was unable to find any evidence of SARS-

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

CoV-2 in the brains of 4 patients with neurological symptoms during acute infection (Kantonen et al., 2020), suggesting that infection of the nervous system may be transient. Another study of acutely infected neuro-COVID patients did not find any SARS-CoV-2 RNA present in the CSF, though they did identify enhanced presence of exhausted T cells and dedifferentiated monocytes (Heming et al., 2021). However, all of these prior studies were conducted on patients with acute SARS-CoV-2 infection as opposed to neuro-PASC, and thus mechanisms for neurological dysfunction may differ. As lumbar punctures or brain biopsies are not indicated in neuro-PASC outpatients, reproducing the above study results in outpatient populations will not be possible. Additional hypotheses for neuro-PASC pathogenesis include a contribution of autoimmune mechanisms which is suggested by the skewed ratio of females to males affected, similar to that seen in rheumatoid arthritis or systemic lupus erythematosus (Chakravarty et al., 2007; Myasoedova et al., 2010), as well as the possibility of persistent SARS-CoV-2 infection in the periphery (Al-Aly et al., 2021). Much of our findings on the SARS-CoV-2 T cell response in neuro-PASC patients supports this latter hypothesis. Ag-specific IFN-γ and IL-2 production was similar between CN and CC groups in response to stimulation by different SARS-CoV-2 Spike peptide pools (Fig. 2A-B). However, T cells from CN patients retained high IFN-y responses to all N- and M-peptide pools tested, while CC subjects had a reactivity limited to N1 and N2 peptide pools with little IFN-y production in response to M pools (Fig. 2C-D). The presence of an immunodominance hierarchy in CC subjects is the expected outcome of an effective memory response to SARS-CoV-2 infection. Studies have shown that while a primary CD4<sup>+</sup> or CD8<sup>+</sup> T cell response to influenza A or LCMV infection is highly diverse and contains T cells reactive to many viral proteins and epitopes, the

memory response preferentially contains T cells responding to specific immunodominant viral

antigens (Sant et al., 2018; Tebo et al., 2005). This effect is more pronounced in the CD8<sup>+</sup> T cell compartment where memory responses are dependent on the ability of dendritic cells to present viral antigen (Crowe et al., 2003) or on antigen availability (Henrickson et al., 2013). The evident lack of a narrow and targeted IFN-γ response to N- and M-peptides in CN patients thus suggests that they are unable to effectively generate a memory response to SARS-CoV-2. Though there were no differences observed in the magnitude or specificity of the IFN-γ response to SARS-CoV-2 Spike peptides, this is somewhat expected as memory T cell responses to Spike protein remain diverse after both infection (Grifoni et al., 2020) and vaccination (Alter et al., 2021). It is additionally not surprising that differences in reactivity were observed for IFN-γ and not IL-2 T cell responses between CN and CC groups (Fig. 2B, E-F). Studies have demonstrated that while Ag-specific T cells produce IL-2 as a proliferation factor, IFN-γ production is largely confined to the memory T cell population (Anthony et al., 2012), which is largely where we see differences in activation and reactivity between groups (Fig. 4).

Antibody production is a key outcome measure after SARS-CoV-2 infection, Tfh cell activation can inform the effectiveness of an antibody response. Stimulation with SARS-CoV-2 N peptides activated Tfh cells in CN but not CC subjects, while the opposite trend was found with M pool stimulation (Fig. 3A-B). Tfh cell activation is crucial to the establishment of germinal centers in secondary lymphoid organs, ultimately resulting in B cell maturation into long-lived plasma cells that can continuously produce class-switched, high-affinity antibodies (Good-Jacobson and Shlomchik, 2010). Studies have demonstrated that the magnitude of the Tfh cell response is dependent on the amount of antigen available and directly correlates with the magnitude of the B cell response (Baumjohann et al., 2013). Indeed, the same CN patients with high N-specific Tfh cell activation also displayed anti-N IgG titers significantly greater than CC

subjects (Fig. 3E) despite the fact that we obtained their samples more than 6 months on average after acute infection. Altogether, these findings are consistent with the presence of a persisting nucleocapsid antigen reservoir resulting in enhanced N-specific Tfh cell activation in CN patients. Clinical reports have identified cases of persistent SARS-CoV-2 infection in the nasopharynx lasting up to 63 days (Bennasrallah et al., 2020) and many patients re-tested RT-PCR+ for SARS-CoV-2 up to 38 days post-discharge (Dao et al., 2021). Though many of our CN patients have not re-tested RT-PCR+ by nasal swab (data not shown), others have yet to be tested. The nasopharynx is not the only possible testing site, however, as there are numerous studies showing that infectious SARS-CoV-2 particles can be detected in fecal matter and can persist for up to 70 days post-symptom onset (Tian et al., 2020; van Doorn et al., 2020). Gastrointestinal symptoms also did not have to be present in order to test RT-PCR+ for SARS-CoV-2 in stool samples (Chen et al., 2020). Thus, it is possible that the gut may also act as a reservoir for persistent SARS-CoV-2 infection which leads to aberrant T cell responses and the development of neuro-PASC.

Effective generation of T cell memory responses is crucial to protect against future infections with the same pathogen. CD8<sup>+</sup> TEM cells from CC subjects retained high levels of activation to all S, N, and M pools assayed while CN patients displayed very little TEM activation (Fig. 4A-B), suggestive of aberrant memory T cell function. Studies on convalescents from the original SARS-CoV epidemic of 2002-03 found that the majority of Ag-specific CD8<sup>+</sup> memory T cells were TEM, and these persisted up to 4 years after infection (Channappanavar et al., 2014). Sterilizing immunity can be a precondition for the development and maintenance of memory T cells because high levels of foreign antigen favor the generation of short-lived effector cells (Mueller et al., 2013), which is why chronic infections often limit the formation

and/or function of memory T cells (Wherry, 2011). In fact, chronic LCMV infection in mice induced aberrantly functioning Ag-specific memory CD8<sup>+</sup> T cells requiring the presence of viral peptide rather than simply the homeostatic cytokines IL-7 and IL-15 to proliferate (Shin et al., 2007; Wherry et al., 2004). The inability of CD8<sup>+</sup> TEM to become activated by antigenic stimulation in CN patients is thus suggestive of a chronic infection state wherein viral antigen can persist but limits the formation of CD8<sup>+</sup> T cell memory. It is also possible that chronic SARS-CoV-2 infection in CN patients leads to memory T cell exhaustion, as shown in chronic HIV and HBV infections in humans (McLane et al., 2019). However, we did not find any differences in the inhibitory marker PD-1 expression on CD8<sup>+</sup> memory T cell subsets between CN and CC patients (data not shown).

Further providing support to the chronic infection hypothesis in neuro-PASC patients, there was a significant elevation in the CD8<sup>+</sup> TEMRA cell population in CN patients over CC or

Further providing support to the chronic infection hypothesis in neuro-PASC patients, there was a significant elevation in the CD8<sup>+</sup> TEMRA cell population in CN patients over CC or HC groups (Fig. 4C). CD8<sup>+</sup> TEMRA cells are a terminally differentiated memory subset that do not traffic through secondary lymphoid organs, and their induction during viral infection can be protective (Tian et al., 2019). Yet, they have also been shown to accumulate during persistent viral infections and contribute to immunosenescence (Derhovanessian et al., 2011). CD8<sup>+</sup> TEMRA cell reactivity to SARS-CoV-2 peptides was also decreased in CN patients over CC subjects. Functionally, the polarization in granzyme production in S3/4-specific CD8<sup>+</sup> TEMRA cells from CC patients (Fig. 4G) suggests higher cytotoxic capacity compared with CN patients and coincides with their higher activation state in Fig. 4E. Ag-specific CD8<sup>+</sup> TEMRA cells are expanded and functionally active in people with significant anti-Dengue virus immunity, and this phenotype is seen as a goal for vaccine-induced protection (Tian et al., 2019). We propose that CD8<sup>+</sup> TEMRA cells are more expanded but less functionally active in CN subjects over CC as a

consequence of inappropriate CD8<sup>+</sup> T cell memory formation, which is lacking in multiple T cell subsets for neuro-PASC patients.

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

We also showed that CD8<sup>+</sup> T cells from CC subjects skewed towards TNF-α production after S pool stimulation compared with CN patients. Comparatively, CN patients displayed significantly more IL-6 production from S-specific CD8<sup>+</sup> T cells (Fig. 4F). Vaccination against the intracellular pathogen Shigella flexneri showed that polyfunctional TNF-α-producing CD8<sup>+</sup> TEM were an important correlate of protection (Toapanta et al., 2018). Despite multiple reports indicating that enhanced TNF-α production is correlated with worse COVID-19 outcomes (Karki et al., 2020, 2021; Pedersen and Ho, 2020), we speculate that Ag-specific TNF-α production is protective in our model system because we are looking at chronically and not acutely infected CN patients. In contrast, IL-6 is known to suppress T<sub>H</sub>1 differentiation (Diehl et al., 2000) and can promote pathogen survival and exacerbate clinical disease during the original SARS-CoV infection (Channappanavar and Perlman, 2017). Indeed, studies in severely ill, hospitalized COVID-19 patients demonstrated that high serum levels of IL-6 significantly correlated with poor clinical outcome (Weiskopf et al., 2020). These data suggest a role for enhanced IL-6 production by CD8<sup>+</sup> T cells in the pathogenesis of neuro-PASC, and open new avenues of research for the treatment of long-COVID through limiting IL-6 activity.

Clinically, neuro-PASC patients reported significantly elevated levels of anxiety, depression, fatigue, sleep disturbance and pain as well as decreased physical function compared with healthy convalescents (Fig. 1C). The severity of these deficits was highly correlated with Ag-specific enhancements in polyfunctionality and decreases in polarization of various memory T cell subsets (Fig. 5, S7). It is possible that T cell function contributes to the genesis and persistence of some of these symptoms. Studies in rodents have shown that T cell activation and

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

function can affect the severity of pain and analgesia (Rosen et al., 2019; Sorge et al., 2015). Indeed, pain is a common hallmark of chronic viral infection (Addis et al., 2020) and recognized among post-COVID sequelae (Kemp et al., 2020); it might follow then that aberrant T cell activation can associate with high pain scores. Additionally, reports have shown that transcriptional programs in immunity and inflammation were differentially regulated in CD4<sup>+</sup> T cells from patients with depression compared with healthy controls (Wang et al., 2015). T<sub>reg</sub> cells may also decrease depressive behavior through negative regulation of inflammation (Miller, 2010), and CN patients do display elevated T<sub>H</sub>1-type cytokine production to S pool stimulation (Fig. 2, 6) while not displaying any compensatory upregulation in T<sub>reg</sub> total numbers or function (data not shown). T cell-derived cytokines can also impact learning and memory. Studies in mouse models of West Nile and Zika viral encephalitis have demonstrated that IFN-y production from CD8<sup>+</sup> T cells in the brain is responsible for neuronal apoptosis and spatial learning deficits (Garber et al., 2019). Thus, there is a precedent for correlating T cell function with cognitive deficits, pain, or depression. Ag-specific cytokine signatures associated with the severity of cognitive and quality of life deficits in neuro-PASC patients may therefore provide some predictive value in terms of clinical outcomes.

Preliminary reports showed that the Pfizer mRNA vaccine could elicit a T cell response 7 days after completion of the full prime-boost protocol (Sahin et al., 2020), but until our studies there has been no data on longitudinal T cell responses primed by vaccination and how these vary between groups with different types of prior SARS-CoV-2 exposure. Our results demonstrate for the first time that vaccine-elicited immune responses are significantly divergent in neuro-PASC versus healthy COVID convalescents (Fig. 6C-D). CN patients consistently had higher antibody titers after receiving the second dose of the vaccine compared with CC and HC

groups, though titers were similar in all groups at 11-15 weeks post-1<sup>st</sup> dose (Fig. 6C). In contrast, the magnitude of Spike-specific IFN-y production by T cells remained high in CN patients out to 4 months post-vaccination while not significantly higher than pre-vaccination levels in CC and HC subjects along the same timeline (Fig. 6D). These data suggest that the mRNA vaccines do not induce robust long-term T cell responses in many individuals, regardless of prior COVID exposure, if they are not neuro-PASC patients. Yet, despite vaccines enhancing Spike-specific IFN-y production in CN T cells, the fact that these responses continue to increase at 15 weeks post-vaccination suggests that CN patients may still have an active SARS-CoV-2 infection or a persistent antigen reservoir rather than developing a robust T cell memory response. These results suggest that alternate SARS-CoV-2 vaccines that induce long-lasting memory T cell responses in previously unexposed individuals as well as healthy COVID convalescents are needed in order to mediate long-term protection from infection. Conversely, vaccination may not be indicated for long-COVID patients who might have a persistent infection as it may be ineffective in the absence of viral clearance. Indeed, current clinical guidance from the CDC recommends that vaccination be delayed until 3 months after acute infection in unvaccinated COVID convalescents. Thus, vaccination strategies that include the memory T cell response as a marker for efficacy should be carefully considered. Together, these data show that irregular Tfh responses, broad scale dysfunction in CD8<sup>+</sup> T cell memory generation and aberrant T cell responses to vaccination are hallmarks of neuro-PASC and require further study to inform treatment and vaccination strategies across the population.

## **Limitations of study**

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

One limitation of our study is the relatively small sample size of unvaccinated neuro-PASC patients. This was due to the wide implementation of SARS-CoV-2 vaccines in the Chicago area soon after beginning study enrollment. Another limitation was not being able to control for time of sample collection with respect to date of COVID-19 symptom onset. As it is possible that neuro-PASC could be the result of a persistent infection, further investigations would require testing of potential cryptic reservoirs, including stool samples from CN patients.

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

**Materials and Methods** Ethics Statement This study was approved by the Northwestern University Institutional Review Board (Koralnik Lab, IRB STU00212583). Informed consent was obtained from all enrolled participants. Samples were de-identified before banking. Study participants, NIH Toolbox, and PROMIS-57 data collection We enrolled consenting unvaccinated adult outpatients seen in the Neuro-PASC-19 clinic at Northwestern Memorial Hospital from September 2020-June 2021, including 56 neuro-PASC "long-hauler" patients with documented PCR+ or seropositive IgG results for SARS-CoV-2 (CN). In parallel, we recruited 24 unvaccinated healthy COVID convalescents from the surrounding community who tested PCR+ for SARS-CoV-2 but had no lingering neurological symptoms (CC) and 31 healthy controls who tested PCR- for SARS-CoV-2 and were also seronegative for IgG against SARS-CoV-2 Spike RBD. All study subjects remained living throughout the period of observation. Heparinized blood samples were collected one time from each subject at an average of 155-315 days post-symptom onset (as in Fig. 1B). Other demographic information is contained in Fig. 1B. CN patients completed a cognitive function evaluation in the clinic coincident or near the date of their blood sample acquisition with the National Institutes of Health (NIH) Toolbox v2.1 instrument, including assessments of: processing speed (pattern comparison processing speed test); attention and executive memory (inhibitory control and attention test); executive function (dimensional change card sort test); and working memory (list sorting working memory test) (Lai et al., 2011; Weintraub et al., 2013).

PROMIS-57 was administered to CN and CC patients an average of 72 days post-sample

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

collection. Both PROMIS-57 and NIH Toolbox results are expressed as T-scores adjusted for age, education, gender, and race/ethnicity with a score of 50 representing the normative mean/median of the US reference population with a standard deviation of 10. Lower cognition Tscores indicate worse performance while higher fatigue, depression, anxiety, or pain interference T-scores indicate greater symptom severity. PBMC and plasma collection 30mL of venous blood from study volunteers was collected in blood collection tubes containing sodium heparin from BD Biosciences. Whole blood was layered on top of 15mL of Histopaque 1077 (Sigma-Aldrich) in 50mL Leucosep blood separation tubes (Greiner Bio-One) and spun at 1000g for 18min at RT. Plasma was collected and stored at -80°C. The PBMC layer was collected and washed 2x in sterile PBS before red blood cell lysis with ACK buffer (Quality Biologicals). PBMCs were used in assays either immediately or frozen down for use in the near term. *SARS-CoV-2 peptide antigens* All S, N and M peptide arrays used in ELISPOT and flow cytometry studies were obtained from BEI Resources, NIAID, NIH: Peptide Array, SARS-Related Coronavirus 2 Spike (S) Protein; NR-52402, Nucleocapsid (N) Protein, NR-52404; Membrane (M) Protein, NR-52403. The S peptide array consisted of 181 peptides of 13-17aa in length and split into 6 sub-pools (S1-S6) containing 30-31 peptides each. The N peptide array consisted of 59 peptides of 13-17aa each split into 3 sub-pools containing 29-30 peptides each. The M peptide array consisted of 31 peptides of 12-17aa and split into 3 sub-pools of 10-11 peptides each (Fig. S1). All peptides were

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

dissolved in either sterile H<sub>2</sub>O or 50% sterile H<sub>2</sub>O-DMSO up to 1mL for a universal 1mg/mL stock concentration. Peptides were used at a final concentration at 2µg/mL in all assays. IgG Spike RBD and Nucleocapsid ELISA Antigen-specific total antibody titers were measured by ELISA as described previously (Dangi et al., 2020; Palacio et al., 2020). In brief, 96-well flat-bottom MaxiSorp plates (Thermo Scientific) were coated with 1 μg/ml of Spike RBD for 48 hr at 4°C. Plates were washed three times with wash buffer (PBS + 0.05% Tween 20). Blocking was performed with blocking solution (PBS + 0.05% Tween 20 + 2% bovine serum albumin), for 4 hr at room temperature. 6  $\mu$ l of sera was added to 144 µl of blocking solution in the first column of the plate, 1:3 serial dilutions were performed until row 12 for each sample, and plates were incubated for 60 min at room temperature. Plates were washed three times with wash buffer followed by addition of secondary antibody conjugated to horseradish peroxidase, goat anti-human IgG (H + L) (Jackson ImmunoResearch) diluted in blocking solution (1:1000) and 100 µl/well was added and incubated for 60 min at room temperature. After washing plates three times with wash buffer, 100 μl/well of Sure Blue substrate (SeraCare) was added for 1 min. Reaction was stopped using 100 µl/well of KPL TMB Stop Solution (SeraCare). Absorbance was measured at 450 nm using a Spectramax Plus 384 (Molecular Devices). SARS-CoV-2 RBD and N proteins used for ELISA were produced at the Northwestern Recombinant Protein Production Core by Dr. Sergii Pshenychnyi using plasmids that were produced under HHSN272201400008C and obtained from BEI Resources, NIAID, NIH: Vector pCAGGS containing the SARS-related coronavirus 2, Wuhan-Hu-1 spike glycoprotein gene (soluble, stabilized), NR-52394 and receptor binding domain (RBD), NR-52309, nucleocapsid gene NR-53507. Cell stimulation and IFN-y/IL-2 ELISPOT

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

Multiscreen-IP plates (Millipore-Sigma) were coated overnight at 4°C with 2µg/mL anti-IFN-y (clone 1-D1K, Mabtech) or 5µg/mL anti-IL-2 (clone MT2A91/2C95, Mabtech), washed with sterile PBS, and blocked with complete RPMI-10% FBS. PBMC isolated from CN, CC, and HC subjects were used either freshly isolated or after thawing and resting overnight in media containing 10ng/µL recombinant human IL-15 (Peprotech) at 37°C, 5% CO<sub>2</sub>. Cells were then plated at a concentration of  $2.5 \times 10^5$  cells/well in  $100 \mu L$  of media and stimulated with the indicated antigen mixtures from SARS-CoV-2 at a concentration of 2µg/mL in complete RPMI medium containing 5% human AB serum (Sigma-Aldrich) and 5ng/mL IL-15. Plates were incubated at 37°C, 5% CO<sub>2</sub> for 20 h and washed 5x with dH<sub>2</sub>O and PBS-0.05% Tween-20 (PBS-T). 2µg/mL biotinylated IFN-y (clone 7-B6-1, Mabtech) or 5µg/mL IL-2 (clone MT8G10, Mabtech) diluted in PBS-10% FBS (PBS-F) was added to the respective wells and plates were incubated for 1.5h at RT. Plates were subsequently incubated for 40 minutes at RT in streptavidin-alkaline phosphatase in PBS-F (Jackson ImmunoResearch) was added after washing plates 5x in PBS-T. ELISPOT plates were developed using an Alkaline Phosphatase Conjugate Substrate Kit according to manufacturer's instructions (Bio-Rad Laboratories, Carlsbad, CA). IFN-γ or IL-2-producing cells were quantified using an ImmunoSpot reader (Cellular Technologies, Ltd., Shaker Heights, OH). Antibodies and Flow Cytometry Fresh or frozen PBMCs isolated from the indicated patient groups were stimulated with antigen mixtures as above for 20-22h at 37°C, 5% CO<sub>2</sub>. For intracellular staining and cytokine detection, the Brefeldin-A Golgi plug (Biolegend) was added at a 1:1000 concentration 2 hours after antigenic stimulation commenced. Cells were washed with PBS-1% BSA after incubation and incubated with the indicated antibodies for surface phenotyping by AIM assay or for intracellular

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

cytokine staining (ICS). Cells from each subject were left unstimulated in medium containing 5ng/mL IL-15 ("background") or stimulated in the presence of the indicated antigens. Fixation and permeabilization was performed using Cytofix/Cytoperm (BD Biosciences). Surface staining was done in the dark at 4°C for 30 minutes, while ICS was done in the dark at RT for 45 minutes. Flow cytometry was conducted on  $2-5x10^5$  cells per condition. Data was acquired on a BD FACSymphony Spectral analyzer and analyzed using FlowJo v10 (BD Biosciences) and SPICE-Pestle (Roederer et al., 2011). Quantification and Statistical Analysis Statistical tests to determine significance are described in figure legends and conducted largely in Prism (GraphPad). For pie graphs or heatmaps generated using SPICE analysis, statistics were determined by Permutation test following unstimulated background subtraction, with additional thresholding of 0.03% to account for noise, using SPICE-Pestle. P-values lower than 0.05 were considered statistically significant. Quantile stratification was performed within group for CN cohort. Clinical data were collected and managed using REDCap electronic data capture tools hosted at Northwestern University Feinberg School of Medicine (Harris et al., 2009). REDCap (Research Electronic Data Capture) is a secure, web-based software platform designed to support data capture for research studies, providing 1) an intuitive interface for validated data capture; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for data integration and interoperability with external sources.

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

Acknowledgements We would like to thank the Flow Cytometry Core Facility at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University supported by Cancer Center Support Grant (NCI CA060553) for their assistance in optimizing antibody panels and help with flow cytometry instrumentation. L.V. was supported by a T32 grant T32AR007611 from the Department of Rheumatology, Northwestern University Feinberg School of Medicine. P.P.M. is supported by a grant from the Emerging and Re-Emerging Pathogens Program (EREPP) at Northwestern University, and a grant from the National Institute on Drug Abuse (NIDA, DP2DA051912). **Author Contributions** Conceptualization L.V. P.P.M. and I.K; Investigation L.V., B.H., Z.O., P.H.L, and N.P.; Formal Analysis L.V., B.H., E.M.L., P.P.M. and N.P.; Resources L.V., P.P.M., I.K., Data Curation L.V.; Writing L.V. with feedback from all authors; Supervision P.P.M and I.K.; Project Administration L.V.; Funding Acquisition L.V., P.P.M, and I.K. **Declaration of Interests** The authors declare no competing interests.

### References

557

- Addis, D.R., DeBerry, J.J., and Aggarwal, S. (2020). Chronic Pain in HIV. Mol Pain 16,
- 559 1744806920927276.
- Ahmed, H., Patel, K., Greenwood, D.C., Halpin, S., Lewthwaite, P., Salawu, A., Eyre, L., Breen,
- A., O'Connor, R., Jones, A., et al. (2020). Long-term clinical outcomes in survivors of severe
- acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after
- hospitalisation or ICU admission: A systematic review and meta-analysis. J Rehabil Med 52,
- 564 jrm00063.
- Al-Aly, Z., Xie, Y., and Bowe, B. (2021). High-dimensional characterization of post-acute
- sequelae of COVID-19. Nature *594*, 259-264.
- Alter, G., Yu, J., Liu, J., Chandrashekar, A., Borducchi, E.N., Tostanoski, L.H., McMahan, K.,
- Jacob-Dolan, C., Martinez, D.R., Chang, A., et al. (2021). Immunogenicity of Ad26.COV2.S
- vaccine against SARS-CoV-2 variants in humans. Nature.
- Anthony, D.D., Milkovich, K.A., Zhang, W., Rodriguez, B., Yonkers, N.L., Tary-Lehmann, M.,
- and Lehmann, P.V. (2012). Dissecting the T Cell Response: Proliferation Assays vs. Cytokine
- 572 Signatures by ELISPOT. Cells 1, 127-140.
- Arnold, D.T., Milne, A., Samms, E., Stadon, L., Maskell, N.A., and Hamilton, F.W. (2021).
- 574 Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute
- 575 Infection: A Case Series. Ann Intern Med.
- Baumjohann, D., Preite, S., Reboldi, A., Ronchi, F., Ansel, K.M., Lanzavecchia, A., and
- 577 Sallusto, F. (2013). Persistent antigen and germinal center B cells sustain T follicular helper cell
- responses and phenotype. Immunity 38, 596-605.

- Bennasrallah, C., Bannour, R., Jlassi, O., Kacem, M., Fredj, M.B., Abroug, H., Zemni, I.,
- Garrach, B., Bahri, R., Charfeddine, N., et al. (2020). Three COVID-19 cases with a long-term
- viral shedding period in Tunisia. Pan Afr Med J *35*, 117.
- Center, J.C.R. (2021). Cumulative worldwide Covid-19 cases (Baltimore, MD: Johns Hopkins
- 583 University of Medicine).
- Chakravarty, E.F., Bush, T.M., Manzi, S., Clarke, A.E., and Ward, M.M. (2007). Prevalence of
- adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained
- using hospitalization data. Arthritis Rheum *56*, 2092-2094.
- 587 Channappanavar, R., and Perlman, S. (2017). Pathogenic human coronavirus infections: causes
- and consequences of cytokine storm and immunopathology. Semin Immunopathol 39, 529-539.
- Channappanavar, R., Zhao, J., and Perlman, S. (2014). T cell-mediated immune response to
- respiratory coronaviruses. Immunol Res *59*, 118-128.
- 591 Chen, H., Hou, J., Jiang, X., Ma, S., Meng, M., Wang, B., Zhang, M., Zhang, M., Tang, X.,
- Zhang, F., et al. (2005). Response of memory CD8+ T cells to severe acute respiratory syndrome
- 593 (SARS) coronavirus in recovered SARS patients and healthy individuals. J Immunol 175, 591-
- 594 598.
- 595 Chen, Y., Chen, L., Deng, Q., Zhang, G., Wu, K., Ni, L., Yang, Y., Liu, B., Wang, W., Wei, C.,
- et al. (2020). The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. J Med
- 597 Virol *92*, 833-840.
- 598 Crowe, S.R., Turner, S.J., Miller, S.C., Roberts, A.D., Rappolo, R.A., Doherty, P.C., Ely, K.H.,
- and Woodland, D.L. (2003). Differential antigen presentation regulates the changing patterns of
- 600 CD8+ T cell immunodominance in primary and secondary influenza virus infections. J Exp Med
- 601 *198*, 399-410.

- Dao, T.L., Hoang, V.T., and Gautret, P. (2021). Recurrence of SARS-CoV-2 viral RNA in
- recovered COVID-19 patients: a narrative review. Eur J Clin Microbiol Infect Dis 40, 13-25.
- Derhovanessian, E., Maier, A.B., Hahnel, K., Beck, R., de Craen, A.J.M., Slagboom, E.P.,
- Westendorp, R.G.J., and Pawelec, G. (2011). Infection with cytomegalovirus but not herpes
- simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in
- 607 humans. J Gen Virol 92, 2746-2756.
- Diehl, S., Anguita, J., Hoffmeyer, A., Zapton, T., Ihle, J.N., Fikrig, E., and Rincon, M. (2000).
- Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity 13, 805-815.
- 610 Duan, Y.Q., Xia, M.H., Ren, L., Zhang, Y.F., Ao, Q.L., Xu, S.P., Kuang, D., Liu, Q., Yan, B.,
- Zhou, Y.W., et al. (2020). Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19
- 612 Patients. Curr Med Sci 40, 618-624.
- 613 Garber, C., Soung, A., Vollmer, L.L., Kanmogne, M., Last, A., Brown, J., and Klein, R.S.
- 614 (2019). T cells promote microglia-mediated synaptic elimination and cognitive dysfunction
- during recovery from neuropathogenic flaviviruses. Nat Neurosci 22, 1276-1288.
- 616 Good-Jacobson, K.L., and Shlomchik, M.J. (2010). Plasticity and heterogeneity in the generation
- of memory B cells and long-lived plasma cells: the influence of germinal center interactions and
- 618 dynamics. J Immunol 185, 3117-3125.
- 619 Goubard, A., Loiez, C., Abe, J., Fichel, C., Herwegh, S., Faveeuw, C., Porte, R., Cayet, D.,
- Sebbane, F., Penet, S., et al. (2015). Superantigenic Yersinia pseudotuberculosis induces the
- expression of granzymes and perforin by CD4+ T cells. Infect Immun 83, 2053-2064.
- 622 Graham, E.L., Clark, J.R., Orban, Z.S., Lim, P.H., Szymanski, A.L., Taylor, C., DiBiase, R.M.,
- Jia, D.T., Balabanov, R., Ho, S.U., et al. (2021). Persistent neurologic symptoms and cognitive
- dysfunction in non-hospitalized Covid-19 "long haulers". Ann Clin Transl Neurol 8, 1073-1085.

- 625 Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings,
- 626 S.A., Sutherland, A., Premkumar, L., Jadi, R.S., et al. (2020). Targets of T Cell Responses to
- 627 SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell
- 628 *181*, 1489-1501 e1415.
- Haas, E.J., Angulo, F.J., McLaughlin, J.M., Anis, E., Singer, S.R., Khan, F., Brooks, N., Smaja,
- 630 M., Mircus, G., Pan, K., et al. (2021). Impact and effectiveness of mRNA BNT162b2 vaccine
- against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a
- nationwide vaccination campaign in Israel: an observational study using national surveillance
- 633 data. Lancet *397*, 1819-1829.
- Halpin, S.J., McIvor, C., Whyatt, G., Adams, A., Harvey, O., McLean, L., Walshaw, C., Kemp,
- 635 S., Corrado, J., Singh, R., et al. (2021). Postdischarge symptoms and rehabilitation needs in
- survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol 93, 1013-1022.
- Hampshire, A., Trender W., Chamberlain SR, Jolly AE, Grant JE, Patrick F, Mazibuko N,
- 638 Williams S, Barnaby JM, Hellyer H, Mehta MA. (2021). Cognitive deficits in people who have
- recovered from COVID-19. EClinicalMedicine.
- Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., and Conde, J.G. (2009). Research
- electronic data capture (REDCap)--a metadata-driven methodology and workflow process for
- providing translational research informatics support. J Biomed Inform 42, 377-381.
- Havervall, S., Rosell, A., Phillipson, M., Mangsbo, S.M., Nilsson, P., Hober, S., and Thalin, C.
- 644 (2021). Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19
- 645 Among Health Care Workers. JAMA *325*, 2015-2016.
- 646 Heming, M., Li, X., Rauber, S., Mausberg, A.K., Borsch, A.L., Hartlehnert, M., Singhal, A., Lu,
- 647 I.N., Fleischer, M., Szepanowski, F., et al. (2021). Neurological Manifestations of COVID-19

- Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. Immunity 54,
- 649 164-175 e166.
- Henrickson, S.E., Perro, M., Loughhead, S.M., Senman, B., Stutte, S., Quigley, M., Alexe, G.,
- Iannacone, M., Flynn, M.P., Omid, S., et al. (2013). Antigen availability determines CD8(+) T
- 652 cell-dendritic cell interaction kinetics and memory fate decisions. Immunity 39, 496-507.
- 653 Higgins, V., Sohaei, D., Diamandis, E.P., and Prassas, I. (2020). COVID-19: from an acute to
- chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci, 1-23.
- 655 Hirschtick, J.L., Titus, A.R., Slocum, E., Power, L.E., Hirschtick, R.E., Elliott, M.R., McKane,
- P., and Fleischer, N.L. (2021). Population-based estimates of post-acute sequelae of SARS-CoV-
- 2 infection (PASC) prevalence and characteristics. Clin Infect Dis.
- Kantonen, J., Mahzabin, S., Mayranpaa, M.I., Tynninen, O., Paetau, A., Andersson, N., Sajantila,
- A., Vapalahti, O., Carpen, O., Kekalainen, E., et al. (2020). Neuropathologic features of four
- autopsied COVID-19 patients. Brain Pathol 30, 1012-1016.
- Karki, R., Sharma, B.R., Tuladhar, S., Williams, E.P., Zalduondo, L., Samir, P., Zheng, M.,
- Sundaram, B., Banoth, B., Malireddi, R.K.S., et al. (2020). COVID-19 cytokines and the
- 663 hyperactive immune response: Synergism of TNF-alpha and IFN-gamma in triggering
- inflammation, tissue damage, and death. bioRxiv.
- Karki, R., Sharma, B.R., Tuladhar, S., Williams, E.P., Zalduondo, L., Samir, P., Zheng, M.,
- Sundaram, B., Banoth, B., Malireddi, R.K.S., et al. (2021). Synergism of TNF-alpha and IFN-
- 667 gamma Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2
- Infection and Cytokine Shock Syndromes. Cell 184, 149-168 e117.
- Kemp, H.I., Corner, E., and Colvin, L.A. (2020). Chronic pain after COVID-19: implications for
- 670 rehabilitation. Br J Anaesth 125, 436-440.

- Klingenstein, M., Klingenstein, S., Neckel, P.H., Mack, A.F., Wagner, A.P., Kleger, A., Liebau,
- S., and Milazzo, A. (2020). Evidence of SARS-CoV2 Entry Protein ACE2 in the Human Nose
- and Olfactory Bulb. Cells Tissues Organs 209, 155-164.
- Ladds, E., Rushforth, A., Wieringa, S., Taylor, S., Rayner, C., Husain, L., and Greenhalgh, T.
- 675 (2020). Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and
- draft quality principles for services. BMC Health Serv Res 20, 1144.
- Lai, J.S., Cella, D., Choi, S., Junghaenel, D.U., Christodoulou, C., Gershon, R., and Stone, A.
- 678 (2011). How item banks and their application can influence measurement practice in
- 679 rehabilitation medicine: a PROMIS fatigue item bank example. Arch Phys Med Rehabil 92, S20-
- 680 27.
- 681 Lam, M.H., Wing, Y.K., Yu, M.W., Leung, C.M., Ma, R.C., Kong, A.P., So, W.Y., Fong, S.Y.,
- and Lam, S.P. (2009). Mental morbidities and chronic fatigue in severe acute respiratory
- 683 syndrome survivors: long-term follow-up. Arch Intern Med *169*, 2142-2147.
- Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chng, M.H.Y.,
- 685 Lin, M., Tan, N., Linster, M., et al. (2020). SARS-CoV-2-specific T cell immunity in cases of
- 686 COVID-19 and SARS, and uninfected controls. Nature 584, 457-462.
- 687 Li, Y.C., Bai, W.Z., and Hashikawa, T. (2020). The neuroinvasive potential of SARS-CoV2 may
- play a role in the respiratory failure of COVID-19 patients. J Med Virol 92, 552-555.
- 689 Liguori, C., Pierantozzi, M., Spanetta, M., Sarmati, L., Cesta, N., Iannetta, M., Ora, J., Mina,
- 690 G.G., Puxeddu, E., Balbi, O., et al. (2020). Subjective neurological symptoms frequently occur
- in patients with SARS-CoV2 infection. Brain Behav Immun 88, 11-16.
- 692 Mahase, E. (2020). Covid-19: What do we know about "long covid"? BMJ *370*, m2815.

- McLane, L.M., Abdel-Hakeem, M.S., and Wherry, E.J. (2019). CD8 T Cell Exhaustion During
- 694 Chronic Viral Infection and Cancer. Annu Rev Immunol 37, 457-495.
- McMahan, K., Yu, J., Mercado, N.B., Loos, C., Tostanoski, L.H., Chandrashekar, A., Liu, J.,
- Peter, L., Atyeo, C., Zhu, A., et al. (2021). Correlates of protection against SARS-CoV-2 in
- 697 rhesus macaques. Nature *590*, 630-634.
- 698 Meckiff, B.J., Ramirez-Suastegui, C., Fajardo, V., Chee, S.J., Kusnadi, A., Simon, H.,
- 699 Eschweiler, S., Grifoni, A., Pelosi, E., Weiskopf, D., et al. (2020). Imbalance of Regulatory and
- 700 Cytotoxic SARS-CoV-2-Reactive CD4(+) T Cells in COVID-19. Cell *183*, 1340-1353 e1316.
- Miller, A.H. (2010). Depression and immunity: a role for T cells? Brain Behav Immun 24, 1-8.
- Mockus, T.E., Ren, H.M., Shwetank, and Lukacher, A.E. (2019). To Go or Stay: The
- Development, Benefit, and Detriment of Tissue-Resident Memory CD8 T Cells during Central
- Nervous System Viral Infections. Viruses 11.
- Muecksch, F., Wise, H., Batchelor, B., Squires, M., Semple, E., Richardson, C., McGuire, J.,
- 706 Clearly, S., Furrie, E., Greig, N., et al. (2021). Longitudinal Serological Analysis and
- Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. J Infect Dis
- 708 *223*, 389-398.
- Mueller, S.N., Gebhardt, T., Carbone, F.R., and Heath, W.R. (2013). Memory T cell subsets,
- 710 migration patterns, and tissue residence. Annu Rev Immunol 31, 137-161.
- 711 Myasoedova, E., Crowson, C.S., Kremers, H.M., Therneau, T.M., and Gabriel, S.E. (2010). Is
- 712 the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-
- 713 2007. Arthritis Rheum *62*, 1576-1582.
- 714 Pedersen, S.F., and Ho, Y.C. (2020). SARS-CoV-2: a storm is raging. J Clin Invest *130*, 2202-
- 715 2205.

- Peng, Y., Mentzer, A.J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T.,
- Supasa, P., Liu, C., et al. (2020). Broad and strong memory CD4(+) and CD8(+) T cells induced
- by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol 21, 1336-
- 719 1345.
- Petersen, M.S., Kristiansen, M.F., Hanusson, K.D., Danielsen, M.E., B, A.S., Gaini, S., Strom,
- M., and Weihe, P. (2020). Long COVID in the Faroe Islands a longitudinal study among non-
- 722 hospitalized patients. Clin Infect Dis.
- Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Perez
- Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA
- 725 Covid-19 Vaccine. N Engl J Med 383, 2603-2615.
- Rasa, S., Nora-Krukle, Z., Henning, N., Eliassen, E., Shikova, E., Harrer, T., Scheibenbogen, C.,
- Murovska, M., Prusty, B.K., and European Network on, M.C. (2018). Chronic viral infections in
- myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). J Transl Med 16, 268.
- Rodda, L.B., Netland, J., Shehata, L., Pruner, K.B., Morawski, P.A., Thouvenel, C.D., Takehara,
- 730 K.K., Eggenberger, J., Hemann, E.A., Waterman, H.R., et al. (2021). Functional SARS-CoV-2-
- 731 Specific Immune Memory Persists after Mild COVID-19. Cell 184, 169-183 e117.
- Roederer, M., Nozzi, J.L., and Nason, M.C. (2011). SPICE: exploration and analysis of post-
- 733 cytometric complex multivariate datasets. Cytometry A 79, 167-174.
- 734 Rosen, S.F., Ham, B., Haichin, M., Walters, I.C., Tohyama, S., Sotocinal, S.G., and Mogil, J.S.
- 735 (2019). Increased pain sensitivity and decreased opioid analysis in T-cell-deficient mice and
- implications for sex differences. Pain 160, 358-366.

- Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L.M., Vormehr, M., Baum, A.,
- Pascal, K., Quandt, J., Maurus, D., et al. (2020). COVID-19 vaccine BNT162b1 elicits human
- antibody and TH1 T cell responses. Nature 586, 594-599.
- Sant, A.J., DiPiazza, A.T., Nayak, J.L., Rattan, A., and Richards, K.A. (2018). CD4 T cells in
- 741 protection from influenza virus: Viral antigen specificity and functional potential. Immunol Rev
- 742 *284*, 91-105.
- Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Stralin, K., Gorin, J.B., Olsson, A.,
- Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020). Robust T Cell
- Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell 183, 158-
- 746 168 e114.
- Shin, H., Blackburn, S.D., Blattman, J.N., and Wherry, E.J. (2007). Viral antigen and extensive
- division maintain virus-specific CD8 T cells during chronic infection. J Exp Med 204, 941-949.
- Sledzinska, A., Vila de Mucha, M., Bergerhoff, K., Hotblack, A., Demane, D.F., Ghorani, E.,
- Akarca, A.U., Marzolini, M.A.V., Solomon, I., Vargas, F.A., et al. (2020). Regulatory T Cells
- 751 Restrain Interleukin-2- and Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4(+) T
- 752 Cells. Immunity *52*, 151-166 e156.
- Song, E., Zhang, C., Israelow, B., Lu-Culligan, A., Prado, A.V., Skriabine, S., Lu, P., Weizman,
- O.E., Liu, F., Dai, Y., et al. (2021). Neuroinvasion of SARS-CoV-2 in human and mouse brain. J
- 755 Exp Med *218*.
- 756 Sorge, R.E., Mapplebeck, J.C., Rosen, S., Beggs, S., Taves, S., Alexander, J.K., Martin, L.J.,
- 757 Austin, J.S., Sotocinal, S.G., Chen, D., et al. (2015). Different immune cells mediate mechanical
- pain hypersensitivity in male and female mice. Nat Neurosci 18, 1081-1083.

- 759 Syed, A., Khan, A., Gosai, F., Asif, A., and Dhillon, S. (2020). Gastrointestinal pathophysiology
- of SARS-CoV2 a literature review. J Community Hosp Intern Med Perspect 10, 523-528.
- 761 Tang, E., Ekundayo, O., Peipert, J.D., Edwards, N., Bansal, A., Richardson, C., Bartlett, S.J.,
- Howell, D., Li, M., Cella, D., et al. (2019). Validation of the Patient-Reported Outcomes
- Measurement Information System (PROMIS)-57 and -29 item short forms among kidney
- transplant recipients. Qual Life Res 28, 815-827.
- Tebo, A.E., Fuller, M.J., Gaddis, D.E., Kojima, K., Rehani, K., and Zajac, A.J. (2005). Rapid
- recruitment of virus-specific CD8 T cells restructures immunodominance during protective
- 767 secondary responses. J Virol 79, 12703-12713.
- Tian, Y., Babor, M., Lane, J., Schulten, V., Patil, V.S., Seumois, G., Rosales, S.L., Fu, Z.,
- Picarda, G., Burel, J., et al. (2017). Unique phenotypes and clonal expansions of human CD4
- effector memory T cells re-expressing CD45RA. Nat Commun 8, 1473.
- 771 Tian, Y., Babor, M., Lane, J., Seumois, G., Liang, S., Goonawardhana, N.D.S., De Silva, A.D.,
- Phillips, E.J., Mallal, S.A., da Silva Antunes, R., et al. (2019). Dengue-specific CD8+ T cell
- subsets display specialized transcriptomic and TCR profiles. J Clin Invest 129, 1727-1741.
- 774 Tian, Y., Rong, L., Nian, W., and He, Y. (2020). Review article: gastrointestinal features in
- 775 COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther *51*, 843-851.
- Toapanta, F.R., Bernal, P.J., Kotloff, K.L., Levine, M.M., and Sztein, M.B. (2018). T cell
- 777 mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD
- 778 1208S in humans. J Transl Med *16*, 61.
- van Doorn, A.S., Meijer, B., Frampton, C.M.A., Barclay, M.L., and de Boer, N.K.H. (2020).
- 780 Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-
- oral transmission. Aliment Pharmacol Ther *52*, 1276-1288.

- Van Elslande, J., Oyaert, M., Ailliet, S., Van Ranst, M., Lorent, N., Vande Weygaerde, Y.,
- Andre, E., Lagrou, K., Vandendriessche, S., and Vermeersch, P. (2021). Longitudinal follow-up
- of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after
- 785 infection. J Clin Virol *136*, 104765.
- Vehar, S., Boushra, M., Ntiamoah, P., and Biehl, M. (2021). Post-acute sequelae of SARS-CoV-
- 2 infection: Caring for the 'long-haulers'. Cleve Clin J Med 88, 267-272.
- Wang, T., Ji, Y.L., Yang, Y.Y., Xiong, X.Y., Wang, I.M., Sandford, A.J., Liang, Z.A., and He,
- J.Q. (2015). Transcriptomic profiling of peripheral blood CD4(+) T-cells in asthmatics with and
- 790 without depression. Gene *565*, 282-287.
- Weintraub, S., Dikmen, S.S., Heaton, R.K., Tulsky, D.S., Zelazo, P.D., Bauer, P.J., Carlozzi,
- N.E., Slotkin, J., Blitz, D., Wallner-Allen, K., et al. (2013). Cognition assessment using the NIH
- 793 Toolbox. Neurology *80*, S54-64.
- Weiskopf, D., Schmitz, K.S., Raadsen, M.P., Grifoni, A., Okba, N.M.A., Endeman, H., van den
- Akker, J.P.C., Molenkamp, R., Koopmans, M.P.G., van Gorp, E.C.M., et al. (2020). Phenotype
- and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory
- 797 distress syndrome. Sci Immunol 5.
- 798 Wherry, E.J. (2011). T cell exhaustion. Nat Immunol *12*, 492-499.
- Wherry, E.J., Barber, D.L., Kaech, S.M., Blattman, J.N., and Ahmed, R. (2004). Antigen-
- 800 independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad
- 801 Sci U S A 101, 16004-16009.

804

805

806

807

808

809

810

811

812

813

814

815

816

817

818

819

820

821

822

823

824

825

**Figure Legends** Figure 1: Study design and clinical data A.) Flow chart describing patient populations and experimental assays for each sample. B.) Table showing patient demographics and neurologic symptoms. C.) PROMIS-57 patient reported survey T scores for CN (n=36) and CC (n=13) groups. D.) NIH Toolbox cognitive T scores for CN (n=43). Horizontal black line represents the U.S. national average T score of 50; p values relative to US national average by one sample Wilcoxon signed rank test. \*p<0.05, \*\*\*p<0.005, \*\*\*\*p<0.0001 by two-tailed Student's t test. Figure 2: Neuro-PASC long-haulers display altered reactivity to SARS-CoV-2 N and M peptides compared to healthy convalescents. A-B.) CN (PCR+ or seropositive neuro-PASC) and CC (PCR+ or seropositive healthy COVID convalescent) groups display similar IFN-y and IL-2 responses to peptides from SARS-CoV-2 Spike protein by ELISPOT. C-D.) CN samples show significantly enhanced IFN-y responses to the N3 peptide pool (C) and to the M1 and M3 peptide pools (D) compared with CC or healthy controls. E-F.) N- and M- specific IL-2 production did not significantly differ between patient subgroups. G.) Spike RBD IgG endpoint titer quantification for CN, CC, and HC groups. LOD is limit of detection. Data representative of 10 experiments with all conditions plated in duplicate. \*p<0.05, \*\*p<0.01, \*\*\*p<0.005, \*\*\*\*p<0.0001 by two-way ANOVA with Tukey's posttest. Figure 3: N-specific CD4<sup>+</sup> Tfh cells are more activated and S-specific CD4<sup>+</sup> T cells display enhanced polyfunctional granzyme production in neuro-PASC long-haulers. A.) FACS plots show that Ag-specific CD4 Tfh from CN patients are more highly activated in response to N peptide pool stimulation compared with CC or HC, but less activated by M peptides. B). Quantification of AIM<sup>+</sup> Tfh cell activation. C-D.) N- and M-specific AIM<sup>+</sup> Tfh cell

827

828

829

830

831

832

833

834

835

836

837

838

839

840

841

842

843

844

845

846

847

848

percentages plotted by time sample obtained post-infection for CN and CC. No correlation was found between these parameters. E.) Anti-SARS-CoV-2 nucleocapsid IgG endpoint titers for CN, CC, and HC subjects shown in 3D. CN patients display significantly elevated anti-N IgG titers compared with CC subjects. F.) Pie graphs show CD4<sup>+</sup> T cells from CC patients have enhanced production of granzymes A, B, & M compared with CN or HC subjects in response to SARS-CoV-2 Spike protein. G.) Heatmap quantifying polyfunctionality in different categories of cytokine production between groups. CC subjects produced 2-fold more granzymes A/B/M than CN patients. Data combined from 6 independent experiments with CN n=35, CC n=11, and HC n=9. \*p<0.05 using one-way ANOVA with Bonferroni's posttest (B) or a Permutation test (E). All pie graphs are showing data after subtracting background (unstimulated condition). Figure 4: Neuro-PASC long-haulers have decreased CD8+ memory T cell activation and function compared with healthy convalescents. A.) Selected FACS plots showing CD8 TEM cells are less activated in CN vs. CC groups after S and N peptide pool stimulation. B.) Quantification of AIM+ CD8 TEM cells after SARS-CoV-2 peptide stimulation. C.) CD8<sup>+</sup> TEMRA cells accumulate significantly in PBMC from CN subjects compared with CC or HC. D.) CD8<sup>+</sup> TEMRA cells from CN patients are less activated by S3/4 and N pools compared with those from CC subjects. E.) Quantification of AIM<sup>+</sup> CD8<sup>+</sup> TEMRA cells from D. F.) Pie charts demonstrating that S3/4-specific CD8<sup>+</sup> TEM are polarized to produce more TNF-α in CC group while those from CN patients produce significantly more IL-6. G.) CD8<sup>+</sup> TEMRA from CC patients are polarized towards category 2 cytokine production in response to S3/4 stimulation compared with CN subjects. Black lines demonstrate boundaries of category 2 cytokine production in each group. Data combined from 5 independent experiments with n=35 CN, n=11 CC. \*p<0.05, \*\*p<0.01 using two-tailed Student's t test with

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866

867

868


869

870


Welch's correction (B, C, E) or permutation test (F, G). All pie graphs are showing data after subtracting background (unstimulated condition). Figure 5: Clinical measures of cognitive dysfunction and depression correlate with altered CD8<sup>+</sup> memory T cell function in neuro-PASC long-haulers. A.) Higher T cell responses to N pool stimulation are positively correlated with high pain scores in CN patients. B.) A positive trend exists between elevated N-specific IFN-y production and higher depression scores in CN patients. C.) CN patients scoring high on pain interference have Spike-specific CD8<sup>+</sup> T cells producing more IL-6 than those scoring low. D.) Heatmap showing CN with low pain scores have Spike-specific CD8<sup>+</sup> T cells producing significantly more granzymes A or B than those reporting high pain levels. E.) Pie graph to demonstrate that CN patients in Q4 for depression have significantly enhanced production of granzymes A/B/M compared with patients with low depression scores. F.) Heatmap demonstrating that CN patients with high depression scores had Spike-specific CD8<sup>+</sup> TEM producing 3-fold higher levels of granzymes A, B, and M or perforin than those scoring low on depression. G.) Spike-specific CD8<sup>+</sup> TCM from CN patients with high scores for executive function are more polarized to produce granzymes A/B/M compared with CN patients from Q1. H.) Heatmap showing Spikespecific CD8<sup>+</sup> TCM in Q1 CN patients are more polyfunctional and produce 8-10x more granzymes A/B/M and perforin than those in Q4. Data representative of 5 independent experiments with n=8-9/quartile. All pie graphs showing Ag-specific cytokine production are background subtracted (unstimulated conditions). \*p<0.05, \*\*p<0.01, \*\*\*\*p<0.001 using Permutation tests.

HC subjects while remaining high in CN patients over time.

A.) Vaccine study visit timeline. V0 was obtained before the first dose of either Pfizer or Moderna mRNA vaccines. V1 and V2 were conducted 3 weeks after the first and second doses, respectively. B.) Vaccine study subject demographics. C.) Longitudinal anti-Spike RBD IgG responses from V0-V4 across groups. Antibody titers are highest in CN patients and wane most quickly in HC subjects. D.) IFN-γ production from Spike-specific T cells do not significantly increase in CC and HC groups while remaining high in CN up to V4 post-vaccination. Total S-specific IFN-γ SFU calculated by averaging responses from each sub-pool for each participant (data in Fig. S9). Data combined from 10 individual experiments with all ELISA conditions done in triplicate and all ELISPOT conditions plated in duplicate. \*p<0.05, \*\*p<0.01, \*\*\*p<0.005, \*\*\*\*p<0.0001 by two-way ANOVA with Tukey's posttest or by two-tailed Student's t test.



Patient Demographics	CN	CC	HC
Participants	56	24	31
Sex	38F, 18M	16F, 8M	19F, 12M
Race/Ethnicity	39 White 9 Hispanic 4 Asian 4 Black	15 White 6 Hispanic 3 Asian	11 White 5 Hispanic 13 Asian 2 Black
Hospitalization (%)	8 (14.3)	1 (4.2)	0 (0)
Days post-symptom onset (range)	193.4 (20-407)	155.0 (44-458)	NA
Neurologic symptoms (%)	56 (100)	0 (0)	0 (0)
Brain Fog	49 (87.5		
Fatigue	46 (82.1)		
Headache	41 (73.2)		
Dizziness	33 (58.9)		
Anosmia	35 (62.5)		
Dysgeusia	33 (58.9)		
Myalgias	34 (60.7)		








Figure 1











Figure 4










Figure 6